PT-141
Also known as: Bremelanotide, Vyleesi
Melanocortin receptor agonist that enhances sexual arousal and desire through central nervous system activation.
Benefits
5
Conditions
5
Evidence
FDA-approved, multiple clinical trials+ studies
Source
Synthetic α-MSH analog
Gabriel Brain Score
Moderate
Overview
Melanocortin receptor agonist that enhances sexual arousal and desire through central nervous system activation.
Mechanism of Action
Activates MC3R and MC4R melanocortin receptors in hypothalamus, increases dopamine release for libido enhancement, sends neuronal impulses via spinal cord for arousal, works centrally (not via peripheral vasodilation).
Key Benefits
- ✓Increases sexual desire and arousal in both sexes
- ✓Works via CNS (not dependent on vascular function)
- ✓Effective for psychological/central causes of dysfunction
- ✓FDA approved for female HSDD
- ✓Rapid onset (30-60 minutes)
Clinical Applications
Dosing Guidelines
Subcutaneous injection
Intranasal
* Dosing should be individualized. Always consult with a qualified healthcare practitioner.
Research & Evidence
FDA-approved, multiple clinical trials
FDA approved for premenopausal women with HSDD. Clinical trials demonstrate efficacy in both sexes. Good safety profile. Unique mechanism compared to PDE5 inhibitors.
Safety Information
Potential Side Effects
- •Nausea
- •Flushing
- •Headache
- •Transient blood pressure increase
- •Injection site reactions
Contraindications
- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy
- Breastfeeding
Interactions
- ⚠Caution with blood pressure medications